Should a patient taking mirtazapine and duloxetine who has painless blurry vision in the right eye, especially in low‑light conditions, be urgently evaluated for acute angle‑closure glaucoma?

Urgent Ophthalmologic Evaluation Required

Yes, this patient requires urgent same-day ophthalmologic evaluation for possible acute angle-closure glaucoma (AACG), given the combination of blurry vision in low-light conditions and concurrent use of two medications (mirtazapine and duloxetine) that are both known to precipitate angle closure. 1, 2

Why This Is Urgent

The presentation of blurry vision specifically worsening in darkness is highly concerning for angle closure. While the absence of pain is somewhat atypical, painless acute angle closure does occur and should not provide false reassurance 3. The dark environment causes pupillary dilation, which can trigger angle closure in susceptible individuals—this patient's symptom pattern of vision problems specifically in low light strongly suggests intermittent angle narrowing or closure.

Medication-Specific Risks

Both of this patient's antidepressants carry significant angle-closure risk:

Duloxetine

• FDA labeling explicitly warns about angle-closure glaucoma risk through pupillary dilation 1
• Multiple case reports document bilateral acute angle closure with duloxetine, occurring as early as 2 days after initiation 4, 5
• Can cause angle closure through both mydriasis and ciliary effusion mechanisms 4
• Recent research shows duloxetine causes statistically significant narrowing of anterior chamber angles even in open-angle eyes 6

Mirtazapine

• FDA labeling warns that pupillary dilation can trigger angle-closure attacks in anatomically susceptible patients 2
• Case reports document bilateral secondary angle closure from ciliary body effusion with mirtazapine use 7
• The angle-closure mechanism differs from classic pupillary block—it involves ciliary body edema and effusion 7

Clinical Presentation Context

According to the 2021 American Academy of Ophthalmology guidelines, acute angle-closure crisis (AACC) classically presents with pressure-induced corneal edema (experienced as blurred vision), mid-dilated pupil, vascular congestion, eye pain, headache, and nausea/vomiting 8. However:

• Not all symptoms need be present
• Blurred vision in darkness suggests intermittent angle narrowing that could progress to full closure
• The absence of pain does not rule out angle closure 3

Immediate Action Required

The patient needs same-day evaluation including:

• Intraocular pressure measurement in both eyes
• Slit lamp examination for corneal edema, mid-dilated pupil, and conjunctival injection
• Gonioscopy to assess angle configuration (the definitive diagnostic test) 8
• Examination of the fellow eye, as medication-induced angle closure is typically bilateral 7, 4, 5

Management If Angle Closure Confirmed

If AACC is diagnosed:

1. Immediate medical treatment with aqueous suppressants, parasympathomimetics, and osmotic agents to lower IOP 8
2. Discontinue both mirtazapine and duloxetine (medication cessation is the primary treatment for drug-induced angle closure) 7, 4, 5, 9
3. Laser peripheral iridotomy for pupillary-block mechanism 8, 4, 5
4. Note: If ciliary body effusion is the mechanism (more common with mirtazapine), peripheral iridotomy is NOT indicated; cycloplegics are preferred over miotics 7, 9
5. Treat the fellow eye prophylactically 8

Critical Pitfall to Avoid

Do not reassure the patient based on absence of pain. The combination of vision changes in darkness plus two high-risk medications creates substantial pre-test probability for angle closure. Delayed diagnosis risks permanent vision loss from optic nerve damage. The recent systematic review emphasizes that serotonergic antidepressants are among the medication classes most consistently implicated in AACG 9.